Janssen ups pressure on PBAC

Janssen is encouraging Australians who suffer major depressive disorder (MDD) as well as their friends and family to share their stories with PBAC ahead of the upcoming July meeting.

The company's submission for Spravato, a nasal spray for depression, will be considered by the committee when it convenes over two days from 6 July.

On average, around one in six Australians, including one in five women and one in eight men, will experience MDD at some point in their lives.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here